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ABSTRACT
Background: Conditional survival (CS) may reveal important differ-
ences in cancer-specific mortality (CSM) among patients with non-
metastatic renal cell carcinoma (nmRCC). This study assessed CS
according to T and N stages in patients treated surgically for nmRCC.
Patients and Methods: Within the SEER database (2001–2015), all
patients with nmRCC treated with either partial or radical nephrec-
tomy were identified. CSM-free estimates according to T and N stage
and substage groupings (pT1aN0–pT4N0 and pTanyN1) and multi-
variable Cox regression models with adjustment for Fuhrman grade
and histologic subtype were assessed. Results: According to T and
N stage and substage groupings, the following patients were in-
cluded in the study: 35,966 (46.2%) with pT1aN0 disease; 18,858
(24.2%) with pT1bN0; 5,977 (7.7%) with pT2aN0; 2,511 (3.2%) with
pT2bN0; 11,839 (15.2%) with pT3aN0; 1,037 (1.3%) with pT3b–cN0;
402 (0.5%) with pT4N0; and 1,302 (1.7%) with pTanyN1. Conditional
CSM-free survival estimates were 98.2% at 1 year versus 98.0% at
10 years of event-free follow-up for patients with pT1aN0 disease,
relative to baseline. Conversely, pT4N0/pTanyN1 conditional CSM-
free survival estimates were 55.8% at 1 year versus 77.9% at 8 years of
event-free follow-up. Attrition due to mortality was highest in patients
with pT4N0/pTanyN1 disease. In multivariable Cox regression anal-
yses, T stage, tumor grade, and histologic subtype represented inde-
pendent predictors, but no interactions were identified. Conclusions:
Tumor stage and its substages represent extremely important deter-
minants of prognosis after lengthy event-free follow-up. The recorded
observations have critical importance for physicians regarding patient
follow-up and counseling.
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Background
Conditional survival (CS) is routinely used in clinical prac-
tice. Specifically, clinicians invariably adjust the prognosis of
individual patients according to the duration of event-free
follow-up. Patients with longer event-free follow-up have
a higher probability of remaining disease-free.1 However,
themagnitude of improved survival is difficult to estimate.
Two studies2,3 address cancer-specific CS in patients
with nonmetastatic renal cell carcinoma (nmRCC): one
is a population-based analysis,2 whereas the other is a
multi-institutional analysis from European and North
American centers of excellence.3 Both studies are limited
by their relatively historical populations. Moreover, the
multi-institutional analysis offers amodel for prediction of
survival rates after nephrectomy in individual patients,3
whereas the population-based analysis provides es-
timates for the AJCC subgroupings.2 Consequently,
neither study allows clinicians to assess CS according
to T and N stage and substage groupings, such as pT1aN0
and pT1bN0. These limitations may be critical with re-
spect to applicability and clinical usefulness.
Based on this unmet need, we investigated cancer-
specific CS rates in a contemporary cohort of surgically
treated patients with nmRCC, identified within the SEER
database (2001–2015). All analyseswere stratified according
to T and N stage and substage groupings. We hypothesized
that important reductions in the risk of 5-year cancer-
specificmortality (CSM)may be identified with increasing
duration of event-free survival (EFS), according to T and
N stage and substage groupings. Specifically, we postu-
lated that patient subgroups may be identified in whom
the risk of CSM is virtually completely eliminated after
EFS of several years.
Patients and Methods
Data Source and Study Population
Within the SEER database (2001–2015),4 we focused on
patients aged $18 years treated with either partial or
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radical nephrectomy as primary treatment for either
pT1aN0–pT4N0 or pTanyN1 nmRCC (ICD-O-3 site codes
C64.9). Death was defined according to the SEER mor-
tality code as either CSM (death from RCC) or other-
cause mortality (death from any other causes). Exclusion
criteria consisted of metastatic RCC; unavailable in-
formation on T and N stage, histology, and Fuhrman
grade; diagnosis only on autopsy or death certificate
only; and missing follow-up data.
Statistical Analyses
Our analyses relied on 2 analytical steps. First, condi-
tional 5-year CSM-free rate was quantified in surgically
treated patients with nmRCC, according to T and N stage
and substage groupings (pT1aN0 vs pT1bN0 vs pT2aN0
vs pT2bN0 vs pT3aN0 vs pT3b–cN0 vs pT4N0/pTanyN1).
CS methodology was applied, as previously reported.1,5
Specifically, CS was calculated as the probability of sur-
vival for x additional years, given y years of accumulated
survival. EFS time points used in the CS models consisted
of from 1 year up to 10 years after surgery. Second, sep-
arate multivariable Cox regression (MCR) models pre-
dicting CSMwere fitted to examine the possible variation
for risk of CSM over time. Specifically, MCR models were
fitted in the overall population at baseline (time zero)
and, subsequently, 8 separate additional MCR models
were fitted in patients who survived 1, 2, 3, 4, 5, 6, 7, and
8 years after surgery. The variables of interest were T and
N stage, Fuhrman grade, and histologic subtype. Additional
adjustment variables consisted of age, sex, ethnicity, and
type of surgery. Finally, we tested for interaction between
Fuhrman grade/histologic subtype and primary risk factor,
namely T and N stages.
All statistical tests were 2-sided with a level of sig-
nificance set at P,.05. Analyses were performed using
R version 3.4.1 (R Foundation for Statistical Computing).
Results
General Characteristics of the Study Population
From 2001 through 2015, 77,892 patients with nmRCC
were identified, 26,562 (34.1%) of whom were treated
with partial nephrectomy and 51,330 (65.9%) with radical
nephrectomy. Stage distribution was as follows: 35,966
patients (46.2%) with pT1aN0; 18,858 (24.2%) with
pT1bN0; 5,977 (7.7%) with pT2aN0; 2,511 (3.2%) with
pT2bN0; 11,839 (15.2%) with pT3aN0; 1,037 (1.3%)
pT3b–cN0; 402 (0.5%) with pT4N0; and 1,302 (1.7%)
with pTanyN1 (Table 1).
Conditional 5-Year CSM Analyses
The baseline (time zero) 5-year CSM-free rate in pT1aN0
cohort (35,966 patients) was 98.2%. Notably, a stable 2%
5-year CSM risk persisted up to 10 years of event-free
follow-up. In pT1bN0 cohort (18,858 patients), a 5%
5-year CSM risk remained stable from beginning up to
10 years of event-free follow-up (Figure 1, Table 2).
Table 1. Patient Characteristics
Variable n (%)
Median age (IQR), y 61 (53–70)
Ethnicity
White 64,190 (82.4)








Never married 11,064 (14.2)







Partial nephrectomy 26,562 (34.1)




















Abbreviation: IQR, interquartile range.
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In the pT2aN0 cohort (n55,977), the 5-year CSM-
free survival probabilities declined from 90.3% at
baseline to 89.5% and 88.7%, respectively, at 60 and
120 months of event-free follow-up. Conversely, in the
pT2bN0 cohort (n52,511), the 5-year CSM-free sur-
vival probabilities increased from 87.3% at baseline to
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Figure 1. Conditional CSM-free survival rates after nephrectomy for patients with (A) pT1aN0, (B) pT1bN0, (C) pT2aN0, (D) pT2bN0, (E) pT3aN0,
(F) pT3b–cN0, and (G) pT4N0/pTanyN1 nonmetastatic renal cell carcinoma.
Abbreviation: CSM, cancer-specific mortality.
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In the pT3aN0 cohort (n511,839), the 5-year CSM-
free survival probabilities increased from 83.2% at base-
line to 89.6% at 120 months of event-free follow-up.
Similarly, in the pT3b–cN0 cohort (n51,037), the 5-year
CSM-free survival probabilities increased from 71.1% at
baseline to 79.4% at 96 months of event-free follow-up.
Finally, in the pT4N0/pTanyN1 cohort (n51,704), the
5-year CSM-free survival probabilities increased from
46.8% at baseline to 77.9% at 96 months of event-free
follow-up (Figure 1, Table 2).
Table 2. Conditional 5-Year CSM-Free Rates and Survival Gains After Surgery
Cohort
Months Survived
0 12 24 36 48 60 72 96 120
pT1aN0
At risk, na 35,966 31,103 27,200 23,439 19,948 16,691 13,765 8,199 4,125
Events, nb 32 108 83 74 78 77 69 48 60
Conditional 5-y CSM-free survival, %a 98.2 98.2 98.1 97.9 97.7 97.7 97.4 97.2 98.0
Survival gain, %c – 10.0 20.1 20.3 20.5 20.5 20.8 21.0 20.2
pT1bN0
At risk, na 18,858 16,257 14,081 12,076 10,204 8,559 6,897 4,195 2,111
Events, nb 20 144 144 128 123 97 101 62 83
Conditional 5-y CSM-free survival, %a 95.1 94.8 94.6 94.4 94.1 93.8 93.7 93.5 95.0
Survival gain, %c – 20.3 20.5 20.7 21.0 21.3 21.4 21.6 20.1
pT2aN0
At risk, na 5,977 5,144 4,503 3,918 3,306 2,766 2,265 1,371 716
Events, nb 15 68 95 90 79 71 49 38 42
Conditional 5-y CSM-free survival, %a 90.3 89.9 89.4 89.1 89.3 89.5 89.1 88.7 88.7
Survival gain, %c – 20.4 20.9 21.2 21.0 20.8 21.2 21.6 21.6
pT2bN0
At risk, na 2,511 2,143 1,839 1,581 1,366 1,148 934 598 –
Events, nb 6 48 67 62 31 25 34 14 –
Conditional 5-y CSM-free survival, %a 87.3 86.5 86.7 87.9 87.7 87.8 87.7 91.1 –
Survival gain, %c – 20.8 20.6 10.6 10.4 10.5 10.4 13.8
pT3aN0
At risk, na 11,839 9,764 8,048 6,658 5,430 4,418 3,413 1,881 879
Events, nb 33 345 393 294 181 159 120 60 78
Conditional 5-y CSM-free survival, %a 83.2 83.8 84.8 85.7 86.3 86.3 87.2 89.5 89.6
Survival gain, %c – 10.5 11.6 12.5 12.9 12.9 14.0 16.3 16.4
pT3b–cN0
At risk, na 1,037 824 697 561 462 386 311 234 –
Events, nb 17 70 51 41 30 22 23 10 –
Conditional 5-y CSM-free survival, %a 71.1 73.7 74.7 76.7 77.8 78.1 80.5 79.4 –
Survival gain, %c – 12.6 13.6 15.6 16.7 17.0 19.4 18.3
pT4N0/pTanyN1
At risk, na 1,704 1,117 771 596 448 345 263 150 –
Events, nb 15 319 169 84 59 34 23 14 –
Conditional 5-y CSM-free survival, %a 46.8 55.8 62.7 65.3 68.5 70.4 69.4 77.9 –
Survival gain, %c – 19.0 115.9 118.5 121.7 123.6 122.6 131.1
Abbreviation: CSM, cancer-specific mortality.
aAt the beginning of the interval.
bAt the end of the interval.
cRelative to baseline.
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Attrition due to mortality was lowest in patients with
pT1aN0 disease (Table 2), as evidenced by conditional
interval-specific CSM-free rates that ranged from 98.2%
to 98.0%, respectively, at baseline and 10 years of event-
free follow-up. Conversely, attrition due to mortality
was highest in patients with pT4N0/pTanyN1 disease,
as evidenced by conditional interval-specific CSM-free
rates that ranged from 46.8% to 77.9%, respectively, at
baseline and 8 years of event-free follow-up.
MCR Models Predicting CSM
InMCRmodels predicting CSM (Figure 2, Table 3), tumor
stage, Fuhrman grade, and histologic subtype were in-
dependent predictors of CSM risk. However, no interac-
tions were identified. Regarding the effect of stage, relative
to the referent pT1N0 stage, the magnitude of decreases
in CSMhazardwas virtually stable for pT2N0 (hazard ratio
[HR], 3.3 at baseline to 2.6 at 96 months of event-free
follow-up), intermediate for pT3N0 (HR, from 4.4 to 2.8,
respectively), and highest for patients with pT4N0/pTanyN1
disease (HR, from 15.2 to 6.7, respectively).
For Fuhrman grade, relative to the referent grade 1,
the CSM hazard was no more significant after 48 months
of EFS for grade 2. Conversely, a decrease in the mag-
nitude of CSM hazard risk was recorded for both grade 3
(HR, from 2.1 at baseline to 1.5 at 96months of event-free
follow-up) and grade 4 (HR, from 3.8 to 2.0, respectively).
Lastly, for histologic subtype, relative to the referent
clear-cell histology, both chromophobe (HR, 0.4 at base-
line to 0.5 at 96 months of event-free follow-up) and
papillary histology (HR, from 0.8 to 0.6, respectively) were
stable. Conversely, the CSM hazard was no more signifi-
cant after 24 months of EFS for sarcomatoid.
Discussion
CS represents an important entity as evidenced by
previous reports in both genitourinary6–8 and other
primaries.1,9,10 This notion was pioneered by Skuladottir
and Olsen1 in patients with lung cancer in 2003. Despite
the importance of CS and its universal use in patient
counseling, only 5 formal studies specifically quantified
CS in patients with RCC.2,3,11–13 Of these, 2 exclusively
focused on metastatic RCC,11,13 showing that despite
the aggressiveness and incurable nature of the disease,
CS represented an important consideration in these pa-
tients, as evidenced by statistically significant and clini-
cally meaningful improvements in CSM11 and overall
mortality,13 provided there was EFS after diagnosis
and/or initiation of systemic therapy.
Of the remaining 3 reports, only 22,3 addressed cancer-
specific CS in nmRCC. Unfortunately, neither of these
2 studies provided stratified estimates of conditional
CSM-free survival according to T and N stage and sub-




























































Figure 2.Multivariable Cox proportional hazards regression predicting CSM after nephrectomy according to (A) tumor stage (referent: pT1N0),
(B) histologic subtype (referent: clear cell), and (C) Fuhrman grade (referent: G1). Additional adjustment variables consisted of age, sex, ethnicity,
and type of surgery.
Abbreviations: CSM, cancer-specific mortality; G, Fuhrman grade.
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important in contemporary urologic practice, becausemost
patients with newly diagnosed nmRCC have been shown
to harbor T1a tumors.14 Moreover, patients with favorable
disease characteristics, such as those with T1a or even T1b
tumors, may have a dramatically different prognosis from
their counterparts with more advanced disease stage.
Nonetheless, equally important prognostic difference in CS
may also exist between substages of T2 or even T3 nmRCC.
Based on these hypotheses, we performed a detailed
analysis of CS within a large contemporary population-
based cohort of nmRCC. Our analysis provided the first
stratified CSM estimates according to T substages and is
summarized as follows.
First, the largest proportion of patients harbor
pT1aN0 (n535,966; 46.2%) and pT1bN0 (n518,858;
24.2%) substages, followed by pT3aN0 (15.2%), pT2aN0
(7.7%), pT2bN0 (3.2%), pTanyN1 (1.7%), pT3b–cN0 (1.3%),
and pT4N0 (0.5%) stage and substages groupings. Con-
sequently, from a clinical and epidemiologic perspective,
stratification according to T and N stage and substage
groupings is particularly important in the most frequent
subgroupings, namely pT1aN0 and pT1bN0. Nonetheless,
from the perspective of individual patient counseling,
stratification of CS based on prognosis is equally impor-
tant in those withmore advanced disease, such as pT3N0,
pT4N0, and even pTanyN1, based on substantially worse
prognoses for these individuals. This point validates the
need for substage stratification of CS.
Second, CS estimates after 5-year EFS ranged from
a maximum of 97.7% to a minimum 70.4% for patients
with pT1aN0 and pT4N0/pTanyN1 disease, respec-
tively. These results illustrate very important hetero-
geneity in the prognosis of surgically treated nmRCC
according to stage and substage groupings, and again
validate the rationale of our study, which reports stage
and substage grouping stratification of CS estimates.
Third, patients with pT1aN0 disease show CS esti-
mates that are virtually unchanged during a 10-year
event-free follow-up (98.2% after 1 year vs 98.0% after
10 years). From a clinical perspective, this implies that
ongoing follow-up of patients with pT1aN0 disease is
based on a 2% CSM risk, indicating that 50 individuals
should be investigated in an ongoing fashion to identify
1 that will eventually die. Despite these low CSM rates,
current European guidelines15 do not define any par-
ticular time point at which follow-up should be inter-
rupted. Similarly, the most recent version of the NCCN
Clinical Practice Guidelines in Oncology (NCCN Guide-
lines) for Kidney Cancer16 at the time of writing did not
recommend a specific cutoff with respect to duration of
follow-up. Instead, follow-up should be tailored based on
patient and tumor characteristics. We identified virtually
the same phenomenon for patients with pT1bN0 disease,
with the exception of CSM risk, which was recorded at 5%.
Fourth, a gradual decrease in CSM rates after periods
of event-free follow-up was recorded in subgroupings
of patients with pT2aN0, pT2bN0, pT3aN0, and pT3b-cN0
disease. Conversely, a more prominent decrease in CSM
rates after shorter periods of event-free follow-up was
recorded for patients with pT4N0/pTanyN1 disease (from
46.8% after 1 year vs 77.9% after 8 years of event-free
follow-up). Consequently, patients with the most ag-
gressive T- and N-stage subgroupings benefit the most
from event-free follow-up. Conversely, patients with the
most favorable T substages (pT1aN0 and pT1bN0) do
not benefit from a decreasing CSM risk event after a
lengthy period of event-free follow-up.
Fifth, we also identified important differences in
CSM during the intervals of observation that distin-
guish patients with specific stages and substages. Highest
CSM was recorded in patients with pT4N0/pTanyN1
disease, as evidenced by conditional interval-specific
CSM-free rates as low as 46.8% initially that eventually
improved to 77.9% after 8 years of event-free follow-up.
Conversely, the lowest CSM was recorded in patients
with pT1aN0 disease, as evidenced by conditional interval-
specific CSM-free rates as high as 98.2% initially that
remained stable at 98.0% after 10 years of event-free
follow-up. These observations validate again the extreme
heterogeneity of prognoses for patients with nmRCC.17
Sixth, very similar findings were recorded after strati-
fication according to Fuhrman grade andhistologic subtype.
Based on the absence of statistically significant interactions
betweenT stage and its substages and either Fuhrman grade
or histologic subtype, we abstained from additional strati-
fication schemes according to those variables.
Several take-home messages warrant consideration.
First, patients with pT1aN0 and pT1bN0 disease showed
the lowest 5-year CSM rates, at 2% and 5%, respectively,
and these did not change with the duration of event-free
follow-up that ranged from 1 to 10 years. Conversely, for
stages pT2aN0 to pT4N0/pTanyN1, event-free follow-up
resulted in higher CSM-free rates. Second, themagnitude
of CSM decrease was most significant in patients with
pT4N0/pTanyN1 disease and least significant in patients
with pT2aN0 disease. Third, in patients with pT2aN0
to pT4N0/pTanyN1 disease, the absolute decrease in CSM
occurred after the shorter event-free follow-up interval in
those with the most advanced stages, whereas it occurred
over the longest interval in those with a less-advanced
stage (pT2aN0). Lastly, the lowest substages (pT1aN0 and
pT1bN0) represent the largest subgroups with the least
attrition due to mortality over time. However, the highest
T and N stage and substage groupings represent the
smallest subgroup; nonetheless, the amount of attrition
due to mortality is the highest. In summary, our find-
ings should be considered in determining the duration
of substage-specific follow-up for surgically treated patients
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with nmRCC disease. To the best of our knowledge, CS
substage-specific follow-up protocols have not been
adopted by either European Association of Urology15
or NCCN16 guidelines, especially for patients with pT1aN0
and pT1bN0 disease.
Despite the strengths of this study, important limi-
tations need to be acknowledged. First, our data repre-
sents a retrospective analysis with high potential for
selection biases. Second, our data that relied on CSM as
an end point do not represent an ideal source for de-
fining a specific surveillance protocol. Instead, recur-
rence and metastatic progression data, which are not
available within the SEER database, should be used for
that purpose. Nonetheless, our findings represent the
most informative method of providing CS probabilities
in surgically treated patients with nmRCC. Therefore,
although our study could not rely on either recurrence or
progression data, clinicians should be aware of changes
in CS according to specific substages and should ideally
incorporate them in decision-making. Third, no infor-
mation about comorbidities is available in the SEER
database. Fourth, because of the SEER coding system, we
could not account for reclassification of AJCC staging
from 2010 onward; we relied on the 6th edition of the
AJCCCancer StagingManual for patients diagnosed from
2001 through 2009 according to the SEER database, and
on the 7th edition for those diagnosed from 2010 onward.
Specifically, adrenal invasion is classified as T3a in the
6th edition versus T4 in the 7th edition. Finally, the
amount of detail is limited relative to smaller institutional
studies. For example, laboratory values and performance
status could not be assessed. However, these limitations
apply to all population-based analyses that were based
on SEER, the National Cancer Database, or other nation-
based data repositories.
Conclusions
CSM risk showed important variability across the range
of examined stage categories. For example, CSM risk of
patients with pT1aN0 disease remained stable, even after
10-year event-free follow-up. Conversely, prognosis for
patients with stage pT4N0/pTanyN1 disease may drasti-
cally improve in proportion to event-free follow-up du-
ration. Our observations have critical importance for
physicians regarding patient follow-up and counseling.
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